Related Experiment Video
Updated: Sep 5, 2025

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
Published on: May 10, 2021
Melatonin Inhibits NF-κB/CREB/Runx2 Signaling and Alleviates Aortic Valve Calcification
Shao-Jung Li1,2,3,4, Wan-Li Cheng2,3,4, Yu-Hsun Kao3,4,5,6
1Division of Cardiovascular Surgery, Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Abstract:
Calcific aortic valve disease (CAVD) is linked to high mortality. Melatonin inhibits nuclear factor-kappa B (NF-κB)/cyclic AMP response element-binding protein (CREB), contributing to CAVD progression. This study determined the role of melatonin/MT1/MT2 signaling in valvular interstitial cell (VIC) calcification. Western blotting and Alizarin red staining were used to analyze NF-κB/CREB/runt-related transcription factor 2 (Runx2) signaling in porcine VICs treated with an osteogenic (OST) medium without (control) or with melatonin for 5 days. Chromatin immunoprecipitation (ChIP) assay was used to analyze NF-κB's transcription regulation of NF-κB on the Runx2 promoter. OST medium-treated VICs exhibited a greater expression of NF-κB, CREB, and Runx2 than control VICs. Melatonin treatment downregulated the effects of the OST medium and reduced VIC calcification. The MT1/MT2 antagonist (Luzindole) and MT1 receptor neutralized antibody blocked the anticalcification effect of melatonin, but an MT2-specific inhibitor (4-P-PDOT) did not. Besides, the NF-κB inhibitor (SC75741) reduced OST medium-induced VIC calcification to a similar extent to melatonin at 10 nmol/L. The ChIP assay demonstrated that melatonin attenuated OST media increased NF-κB binding activity to the promoter region of Runx2. Activation of the melatonin/MT1-axis significantly reduced VIC calcification by targeting the NF-κB/CREB/Runx2 pathway. Targeting melatonin/MT1 signaling may be a potential therapeutic strategy for CAVD.
Insights
Melatonin, a hormone, reduces calcification in heart valve cells by inhibiting key proteins. Targeting the melatonin MT1 receptor shows promise for treating calcific aortic valve disease (CAVD).
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Endocrinology
Background:
- Calcific aortic valve disease (CAVD) is a significant cause of mortality.
- Melatonin is known to inhibit pathways like nuclear factor-kappa B (NF-κB) and cyclic AMP response element-binding protein (CREB), which are implicated in CAVD progression.
Purpose of the Study:
- To investigate the role of melatonin signaling, specifically through MT1 and MT2 receptors, in the calcification of valvular interstitial cells (VICs).
- To elucidate the molecular mechanisms by which melatonin affects VIC calcification, focusing on the NF-κB/CREB/runt-related transcription factor 2 (Runx2) pathway.
Main Methods:
- Porcine VICs were cultured in osteogenic medium with or without melatonin.
- Western blotting and Alizarin red staining were employed to assess protein expression and calcification levels.
- Chromatin immunoprecipitation (ChIP) assays were performed to analyze NF-κB binding to the Runx2 promoter.
Main Results:
- Osteogenic medium significantly increased the expression of NF-κB, CREB, and Runx2, and promoted VIC calcification.
- Melatonin treatment downregulated these osteogenic markers and reduced VIC calcification.
- The anticalcification effect of melatonin was dependent on MT1 receptor activation, as indicated by blockade with Luzindole and an MT1-specific antibody, but not an MT2 inhibitor.
- Melatonin attenuated NF-κB binding to the Runx2 promoter.
Conclusions:
- Melatonin, via the MT1 receptor, inhibits VIC calcification by suppressing the NF-κB/CREB/Runx2 signaling pathway.
- Targeting the melatonin/MT1 axis presents a potential therapeutic strategy for managing calcific aortic valve disease.
More Related Videos
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Co-activators and Co-repressors
Nitric Oxide Signaling Pathway

